A team of researchers from the University of Tennessee Graduate School of Medicine has spent more than two decades investigating systemic amyloidosis, a rare and often fatal disorder with few treatments. Their work played an integral role in moving discoveries out of the lab and into clinical trials, helping launch a biopharmaceutical company focused on (read more)
UT Graduate School of Medicine
UTRF Licensee Attralus Secures $25M in Investment
Professor Jonathan Wall and his team at the UT Graduate School of Medicine have spent more than two decades investigating systemic amyloidosis. Their work played an integral role in helping launch the biopharmaceutical company Attralus with technology licensed from UTRF. Today, Attralus announced that it has secured $25 million in investment financing to work on (read more)
UTRF 2018 Innovation Awards Celebrate UT Researchers
The University of Tennessee Research Foundation (UTRF) celebrated the researchers whose achievements made 2018 a record-breaking year at the annual Innovation Awards ceremonies, held December 4 at the University of Tennessee Health Science Center in Memphis and December 5 at The Foundry on the Fair Site in Knoxville. The Innovation Awards recognize the researchers from (read more)